MedTrace Logo

Smoking Cessation After Acute Coronary Syndrome

NCT03209622 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2021-05-11

No results posted yet for this study

Summary

A randomized controlled trial was conducted in cardiology department and smoking cessation center of University Hospital of Monastir (Tunisia). All smokers Hospitalized for ACS were included. Participants were randomly assigned to either group "A", initiating Nicotine replacement therapy (NRT) in intra-hospitalization or a control group "B" that received NRT after hospital discharge. The end point assessment was smoking abstinence at 24 weeks following randomization, defined as self-reported abstinence in the past week before the 24 week clinic visit confirmed by a measured exhaled carbon monoxide ≤8 ppm. Data were analyzed by intention to treat.

Conditions

  • Smoking
  • Acute Coronary Syndrome
  • Recurrence

Interventions

PROCEDURE

Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge

when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B

DRUG

Nicotine patch

Arm A

OTHER

the external consultation

without patch

Sponsors & Collaborators

  • University of Monastir

    lead OTHER

Principal Investigators

  • Aymen Elhraiech, A. professor · University hospital of Monastir: Avenue Farhat HACHED 5000 Monastir Tunisia

  • Asma Sriha Belguith, Professor · University hospital of Monastir: Avenue Farhat HACHED 5000 Monastir Tunisia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-02
Primary Completion
2017-11-01
Completion
2019-12-30

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03209622 on ClinicalTrials.gov